Cisplatin induces differentiation in teratomas derived from pluripotent stem cells

Kurata, Atsushi; Takanashi, Masakatsu; Ohno, Shinya; Fujita, Koji; Kuroda, Masahiko

doi:10.1016/j.reth.2021.05.005

Cited by 3 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…91 of the 93 patients (97.8%) with non dysgerminomatous tumors were clinically disease free [4]. Administration of cisplatin can reduce the components of immature cells in teratoma derived from embryonic stem cells and pluripotent stem cells which are believed to cause apoptosis and also induce differentiation [2].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Growing Teratoma Syndrome, A Rare Case

2022

BJSTR

View full text Add to dashboard Cite

Introduction: Germ cell is ovarian malignancy that occurs in a woman, especially at the young age women. Immature teratoma is the second most common malignancy in cases of germ cell. Immature teratoma has a good cure rate after proper treatment, namely surgery and chemotherapy. Growing teratoma syndrome (GTS) is a rare condition among patients with immature teratoma which is characterized by enlargement or appearance of a new mass after adequate systemic chemotherapy, normal tumor serum markers, and mass histopathology results show the appearance of mature teratoma in the new mass.Case Illustration: It is reported that an 18-year-old, unmarried woman came to the gynecological oncology polyclinic for routine control with complaints of abdominal pain and a palpable lump in the lower abdomen. A history of undergoing unilateral salpingo-oophorectomy surgery in 2019, with histopathological results of immature teratoma and underwent completed chemotherapy with Bleomycin, Etoposide and Cisplatin regimens for 6 cycles. Ultrasound evaluation showed the appearance of a new mass, but tumor markers Alpha fetoprotein and β hCG were normal. The patient underwent mass resection and was found to be in accordance with the condition of Growing Teratoma Syndrome.Discussion: New mass presence in a patient with a history of immature teratoma was a condition that must be evaluated. The hypothesis GTS can occur because chemotherapy treatment can only destroy malignant cells but cannot destroy benign cells. Treatment of GTS is multi approach disciplinary, including chemotherapy and surgery. Conclusion:Immature teratoma can leave residual disease which will later become a rare complication, namely growing teratoma syndrome. Treatment of GTS is represented by a multi-disciplinary approach, which includes chemotherapy and surgery. common types of germinal malignancies include dysgerminoma and

show abstract

Section: Discussionmentioning

confidence: 99%

“…Treatment were surgery and chemotherapy. This malignancy has a fairly good cure rate among ovarian malignancies [2].…”

Section: Introductionmentioning

confidence: 99%

Growing Teratoma Syndrome, A Rare Case

2022

BJSTR

View full text Add to dashboard Cite

show abstract

Smooth muscle differentiation of coronary intima in autopsy tissues after sirolimus-eluting stent implantation

Kurata

Harada

Fujita

et al. 2023

Cardiovascular Pathology

View full text Add to dashboard Cite

Insights on Lipomatosis after Platinum-Based Chemotherapy Use in Pediatric Oncology: A Case Report

Boeriu

Boc

Borda³

et al. 2022

Medicina

View full text Add to dashboard Cite

Agents of platinum-based chemotherapy, such as cisplatin or carboplatin, are used in the treatment of a wide range of malignancies that affect children, such as brain tumors, osteosarcoma, neuroblastoma, hepatoblastoma, and germ cell tumors (GCTs). The Cyclophosphamide Equivalent Dose (CED) calculator for reproductive risk does not take platinum-based chemotherapy into account, despite the fact that it accounts for the majority of chemotherapy medications that are typically administered for pediatric GCTs. As a result, exposure to platinum-based drugs throughout infancy can have predictable long-term effects such as infertility, as well as other rare encounters such as lipoma formation and lipomatosis. Lipomas are the most prevalent benign soft tissue tumor subtype. They may be either solitary entities or engaged in multiple lipomatosis, which may have a familial origin or be an acquired disorder. Chemotherapy is a possible cause of lipomatosis. Chemotherapy based on cisplatin has been linked to a variety of long-term consequences, including kidney damage, neurotoxicity, and pulmonary toxicity, and may even create secondary cancers. However, lipoma development is known to occur in fewer than 1 in 100 individuals, and only a few examples of multiple cutaneous lipomatosis triggered by this therapy have been documented. Here we present a very rare case of lipomatosis in a pediatric patient with GCT under cisplatin therapy, which might be the third report of this kind affecting children.

show abstract

Cisplatin induces differentiation in teratomas derived from pluripotent stem cells

Cited by 3 publications

References 29 publications

Growing Teratoma Syndrome, A Rare Case

Growing Teratoma Syndrome, A Rare Case

Smooth muscle differentiation of coronary intima in autopsy tissues after sirolimus-eluting stent implantation

Insights on Lipomatosis after Platinum-Based Chemotherapy Use in Pediatric Oncology: A Case Report

Contact Info

Product

Resources

About